Latest Publications
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Stetka J, Usart M,Kubovcakova L,Rai S, Nageswara Rao T, Sutter J, Hao-Shen H,Dirnhofer S, Geier F, Bader M, Passweg J, Manolova V, Dürrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C and Skoda R. Blood. 2023 Apr 27;141(17):2127-2140. doi: 10.1182/blood.2022017976. IF 25.669. 27.04.23 pubmed.ncbi.nlm.nih.gov/36758212/ |
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer. Auf der Maur P, Trefny MP, Baumann Z, Vulin M, Correia AL, Diepenbruck M, Kramer N, Volkmann K, Preca BT, Ramos P, Leroy C, Eichlisberger T, Buczak K, Zilli F, Okamoto R, Rad R, Jensen MR, Fritsch C, Zippelius A, Stadler MB, Bentires-Alj M. Cell Rep Med. 2023 Apr 18;4(4):101002. doi: 10.1016/j.xcrm.2023.101002. Epub 2023 Apr 11. PMID: 37044095 IF 16.988 18.04.23 pubmed.ncbi.nlm.nih.gov/37044095/ |
DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations. Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Feng FY, Gillessen S, Ng CKY, Rubin MA, Piscuoglio S. Cancer Res. 2023 Apr 14;83(8):1203-1213. doi: 10.1158/0008-5472.CAN-22-2236. IF 13.312. 14.04.23 pubmed.ncbi.nlm.nih.gov/36749655/ |
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. Holze F, Becker AM, Kolaczynska KE, Duthaler U and Liechti ME. Clin Pharmacol Ther. 2023 Apr;113(4):822-831. doi: 10.1002/cpt.2821. Epub 2022 Dec 31. IF 7.051. 01.04.23 pubmed.ncbi.nlm.nih.gov/36507738/ |